Literature DB >> 20611034

Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177.

Yoninah S Cramer, Susan L Rosenkranz, Stephen D Hall, Lynda A Szczech, Valerianna Amorosa, Samir K Gupta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20611034      PMCID： PMC2912759          DOI： 10.1097/QAI.0b013e3181e2d5e5

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  3 in total

1.  Pharmacokinetic of nevirapine in haemodialysis.

Authors:  H Izzedine; V Launay-Vacher; G Aymard; M Legrand; G Deray
Journal:  Nephrol Dial Transplant       Date:  2001-01       Impact factor: 5.992

2.  Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

Authors:  R L Murphy; J P Sommadossi; M Lamson; D B Hall; M Myers; A Dusek
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

3.  The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.

Authors:  Samir K Gupta; Susan L Rosenkranz; Yoninah S Cramer; Susan L Koletar; Lynda A Szczech; Valerianna Amorosa; Stephen D Hall
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177
  3 in total
  4 in total

1.  The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection.

Authors:  Jason J Schafer; Saranyu Ravi; Evelyn V Rowland; Germin Shenoda; Nicholas Leon
Journal:  P T       Date:  2011-06

Review 2.  Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.

Authors:  Dario Cattaneo; Cristina Gervasoni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

3.  A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.

Authors:  Maïlys De Sousa Mendes; Gabrielle Lui; Yi Zheng; Claire Pressiat; Deborah Hirt; Elodie Valade; Naïm Bouazza; Frantz Foissac; Stephane Blanche; Jean-Marc Treluyer; Saik Urien; Sihem Benaboud
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

Review 4.  Pharmacotherapeutic options for kidney disease in HIV positive patients.

Authors:  Anam Tariq; Hannah Kim; Hashim Abbas; Gregory M Lucas; Mohamed G Atta
Journal:  Expert Opin Pharmacother       Date:  2020-09-21       Impact factor: 4.103
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.